Pharmaron Beijing Co., Ltd. logo

Pharmaron Beijing Co., Ltd.

3759.HK

HKSEHealthcareBiotechnology

Latest quote

HK$31.26

−HK$1.94 · -5.84%

Aug 24, 11:59 AM HKT

3759.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Bo Liang Lou
Listed since
Nov 28, 2019
Employees
25,088

Market position

Day range

Current HK$31.26

52-week range

Current HK$31.26

Open
HK$33.20
Previous close
HK$33.20
Volume
6.31M
0.82× average
Average volume
7.66M
Average daily volume
Market cap
85.31B HKD
Beta
0.62
Market reference 1
50-day average
HK$22.705
+37.68% above average
200-day average
HK$21.0007
+48.85% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
33.4B CNY
P/E (TTM)
46.51×
P/B (TTM)
5.07×
P/S (TTM)
4.39×
EV / EBITDA
10.16×
Earnings yield
5.37%
Free cash flow yield
1.78%
Dividend yield
0.44%

Profitability & efficiency

Gross margin
33.27%
Operating margin
13.49%
Net margin
11.27%
Return on equity
11.05%
Return on assets
6.14%
Return on invested capital
7.84%

Financial health

Debt / equity
0.43×
Current ratio
0.93×
Altman Z-score
5.17
Piotroski F-score
6 of 9

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
+5.16%
11 comparable reports
Latest EPS result
0.27
Estimate 0.28 · Miss by 3.53%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.380.30.220.14Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 25, 2025: actual 0.21, estimate 0.27, surprise -22.22%, Miss. Q2 2025, reported Apr 27, 2025: actual 0.17, estimate 0.2, surprise -15.00%, Miss. Q3 2025, reported Aug 21, 2025: actual 0.22, estimate 0.245, surprise -10.22%, Miss. Q4 2025, reported Oct 28, 2025: actual 0.249, estimate 0.25, surprise -0.48%, Miss. Q1 2026, reported Mar 30, 2026: actual 0.3, estimate 0.28, surprise +7.14%, Beat. Q2 2026, reported Apr 28, 2026: actual 0.212, estimate 0.24, surprise -11.40%, Miss. Q3 2026, reported Aug 20, 2026: actual 0.268, estimate 0.278, surprise -3.53%, Miss. Q4 2026, reported Oct 22, 2026: actual —, estimate 0.338, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.25B4.47B3.68B2.9BQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 25, 2025: actual 3.46B HKD, estimate 3.27B HKD, surprise +5.61%, Beat. Q2 2025, reported Apr 27, 2025: actual 3.1B HKD, estimate 3.34B HKD, surprise -7.11%, Miss. Q3 2025, reported Aug 21, 2025: actual 3.34B HKD, estimate 3.3B HKD, surprise +1.19%, Beat. Q4 2025, reported Oct 28, 2025: actual 3.59B HKD, estimate 3.48B HKD, surprise +3.22%, Beat. Q1 2026, reported Mar 30, 2026: actual 4.01B HKD, estimate 3.98B HKD, surprise +0.70%, Beat. Q2 2026, reported Apr 28, 2026: actual 4.1B HKD, estimate 3.98B HKD, surprise +3.12%, Beat. Q3 2026, reported Aug 20, 2026: actual 4.68B HKD, estimate 4.61B HKD, surprise +1.55%, Beat. Q4 2026, reported Oct 22, 2026: actual —, estimate 5.05B HKD, surprise —, Comparison unavailable.

3759.HK peers

ETFs holding 3759.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 3759.HK

research.disclaimer